XML 46 R36.htm IDEA: XBRL DOCUMENT
v3.21.2

Revenues (Details) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2021 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2021 USD ($) segment | Sep. 30, 2020 USD ($)
Revenue from Contract with Customer [Abstract] |  |  |  |
Number of operating segments | segment |  |  | 1 |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | $ 6,706 | $ 6,423 | $ 19,133 | $ 18,790
Product sales [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 6,320 | 6,104 | 18,026 | 17,906
Product sales [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 4,558 | 4,618 | 12,835 | 13,325
Product sales [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 1,762 | 1,486 | 5,191 | 4,581
Enbrel® (etanercept) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 1,289 | 1,325 | 3,357 | 3,724
Enbrel® (etanercept) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 1,263 | 1,289 | 3,270 | 3,619
Enbrel® (etanercept) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 26 | 36 | 87 | 105
Prolia® (denosumab) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 803 | 701 | 2,375 | 2,014
Prolia® (denosumab) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 530 | 478 | 1,569 | 1,341
Prolia® (denosumab) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 273 | 223 | 806 | 673
Otezla (apremilast) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 609 | 538 | 1,619 | 1,578
Otezla (apremilast) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 495 | 439 | 1,284 | 1,280
Otezla (apremilast) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 114 | 99 | 335 | 298
XGEVA® (denosumab) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 517 | 481 | 1,473 | 1,397
XGEVA® (denosumab) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 372 | 363 | 1,061 | 1,036
XGEVA® (denosumab) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 145 | 118 | 412 | 361
Neulasta® (pegfilgrastim) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 415 | 555 | 1,383 | 1,757
Neulasta® (pegfilgrastim) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 360 | 484 | 1,215 | 1,538
Neulasta® (pegfilgrastim) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 55 | 71 | 168 | 219
Aranesp® (darbepoetin alfa) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 396 | 384 | 1,118 | 1,193
Aranesp® (darbepoetin alfa) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 149 | 158 | 409 | 489
Aranesp® (darbepoetin alfa) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 247 | 226 | 709 | 704
Repatha (evolocumab) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 272 | 205 | 844 | 634
Repatha (evolocumab) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 139 | 92 | 421 | 331
Repatha (evolocumab) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 133 | 113 | 423 | 303
KYPROLIS® (carfilzomib) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 293 | 260 | 824 | 793
KYPROLIS® (carfilzomib) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 198 | 173 | 547 | 527
KYPROLIS® (carfilzomib) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 95 | 87 | 277 | 266
Other products [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 1,726 | 1,655 | 5,033 | 4,816
Other products [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 1,052 | 1,142 | 3,059 | 3,164
Other products [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | 674 | 513 | 1,974 | 1,652
Other revenues [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | $ 386 | $ 319 | $ 1,107 | $ 884

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599 + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_EnbrelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_ProliaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_OtezlaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_XgevaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_NeulastaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_AranespMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_KyprolisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |